logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11690825 B1

PDFFull Text
Date of Patent:
Jul. 04, 2023

Filed:

Mar. 08, 2017

20-hete receptor (gpr75) antagonists and methods of use

Applicants:

Board of Regents, the University of Texas System, Austin, TX (US);

New York Medical College, Valhalla, NY (US);

Inventors:

John R. Falck, Austin, TX (US);

Michal L. Schwartzman, Valhalla, NY (US);

Victor Garcia, Valhalla, NY (US);

Assignees:

Board of Regents, The University of Texas System, Austin, TX (US);

New York Medical College, Valhalla, NY (US);

Attorney:

Dentons US LLP

Primary Examiner:

Theodore R Howell

Int. Cl.
CPC ...
A61K 31/201 (2006.01); C07C 59/42 (2006.01); A61K 31/41 (2006.01); A61K 47/54 (2017.01); A61P 13/12 (2006.01); A61K 31/197 (2006.01); C07C 233/49 (2006.01); C07C 247/12 (2006.01); C07D 257/06 (2006.01); C40B 40/04 (2006.01); C07K 14/72 (2006.01); C40B 30/04 (2006.01); G01N 33/92 (2006.01); C07D 257/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/41 (2013.01); A61K 31/197 (2013.01); A61K 31/201 (2013.01); A61K 47/542 (2017.08); A61P 13/12 (2018.01); C07C 59/42 (2013.01); C07C 233/49 (2013.01); C07C 247/12 (2013.01); C07D 257/04 (2013.01); C07D 257/06 (2013.01); C07K 14/723 (2013.01); C40B 30/04 (2013.01); C40B 40/04 (2013.01); G01N 33/92 (2013.01); G01N 2333/705 (2013.01); G01N 2500/00 (2013.01);
Abstract

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

Find Patent Forward Citations

Falck, John. (2023). 20-hete receptor (gpr75) antagonists and methods of use (U.S. Patent No. 11690825). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11690825

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…